Antengene to Start Trial of PD-L1/4-1BB Bispecific in Solid Tumors and NHL

Shanghai 's Antengene was approved to start an Australian Phase I trial of its PD-L1/4-1BB bispecific antibody. The trial will evaluate the safety and tolerability of ATG-101 as a single agent in patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma. Antengene, which developed ATG-101 in-house and continues to hold global rights to the candidate, plans to file INDs for China and US trials of ATG-101 later this year. More details.... Stock Symbol: (HK: 6996) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.